NIIMBL Announces RFA for Optimizing Long-read Next Sequencing Capabilities

DNA strand

NEWARK, Del., March 4, 2025 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce a Request for Applications (RFA) to participate in its Viral Vector Program’s initiative on optimizing long-read next generation sequencing (NGS) capabilities. With the emergence of gene therapies as a treatment option for a variety of health […]

NIIMBL is accepting applications for the 2025 eXperience

NIIMBL eXperience logo

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce student applications for the 2025 NIIMBL eXperience are now open. Students can apply to one of seven unique programs across the U.S.

NIIMBL Awards $600K for 7 eXperience Programs in 2025

NIIMBL eXperience logo

NIIMBL is pleased to announce it has awarded $600K to launch seven NIIMBL eXperience programs in regions throughout the United States during the summer of 2025. Each location will host a week-long program, designed to foster diversity within the biopharmaceutical industry and introduce first- and second-year college students to new career possibilities.

NIIMBL collaborates on review of vaccine process technology developments

Vaccine and vile. NIIMBL publishes 10-year lookback at vaccine process technology.

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published “Vaccine process technology—a decade of progress” in Biotechnology and Bioengineering. The paper serves as an update to a 2012 review titled “Vaccine process technology” authored by NIIMBL Executive Director Barry Buckland and explores transformations in vaccine development over the past decade.

NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects

NEWARK, Del., April 9, 2024 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce approximately $10M in planned project activities through the Institute’s Project Call 7.1 for eight new technology and workforce development projects that will help address key opportunities for innovation in biopharmaceutical manufacturing.